New Order, New Positioning, New Engine | Dalton Venture 2023 Annual Partners Meeting Successfully Held
One gathering closes, another horizon opens. Keep exploring the boundless frontier of innovation!
道彤投资
@daltonventure
以生命科学为根，向硬科技生长
88 articles
Articles
Mountains, Rivers, and Dreams — Measured in Steps | Dalton Venture 2023 Outing Notes
Running down the hard but right path, staying focused with enduring passion.
Inside the Dalton Family | Mu Liyue of Lanji Medical: From Silicon Valley Back to Xi'an, I Want to Build a Laser Product That Truly Matters to Medicine
Changing the World Through "Medicine-Engineering Integration"
Into the Dalton Family | Exclusive Interview with BioChuang: Pioneering the EDP Technology Platform to Produce High-Performance Chinese "Membranes" --- Walking into the Dalton Family | Exclusive Interview with BioChuang: First-in-Class EDP Technology Platform, Producing High-Performance Chinese "Membranes"
World's First Electrochemical Deposition (EDP) Technology Platform
Inside Dalton Venture's Family of Companies | Boosting Long-Term Survival Rates with a Single Injection: How This Innovative Drug Developer Is Taking on Leukemia
CAR-T cell therapy is seen as a new hope in humanity's fight against cancer.
Into the Dalton Venture Family | Leveraging Two Technology Platforms — Low-Temperature Plasma and Radiofrequency Ablation — Favamed Charts a Platform Strategy
As of today, Fangrun Medical and its subsidiaries have secured 19 NMPA registrations. Its products are now used in over 1,200 hospitals across China, with successful exports to Europe and Southeast Asia, serving more than 100,000 patients annually.
Over 50,000 Cases in a Single Day! Inside the Speed of Landing AI's Cervical Cancer Screening | Dalton Venture Family
Landing Med aims to automate, digitize, and scale cytological pathology diagnosis through AI-powered, cloud-based diagnostic technology — enabling intelligent, networked, and standardized early detection of high-incidence tumors.
Into the Dalton Family | Melody Medical: Opening a New Chapter in RDN Therapy, Netrod® — China's Original Innovation — Takes the Global Stage
Hypertension is one of the most common diseases worldwide, severely impacting patients' health and quality of life. Nearly **1.28 billion adults** globally suffer from hypertension, yet awareness of the condition stands at just **54%**. Over 700 million hypertensive patients remain untreated, and only **21%** of adults with hypertension have their blood pressure under control. Prevention and treatment of hypertension carries profound significance for patients, families, and society at large.
Dalton Venture's Sun Qi: Prioritize Hard-Tech Sectors That Serve National Needs, Prioritize Solving Supply Chain Security Issues | Dalton Insights
At the "2023 China Investment Annual Conference" summit, Sun Qi shared his perspectives and experience with fellow guests on the topic of *How Much Longer Is the Window for Domestic Substitution in Medical Devices?*
A Visit to a Dalton Venture Family Company | Heyuan Bio's Lulu Lyu: China's Homegrown CAR-T Therapy Is About to Become Reality, Bringing New Hope for Relapsed or Refractory Acute Lymphoblastic Leukemia Patients
"After nearly five years, He Yuan Bio's first core product, inaticabtagene autoleucel injection, has treated more than 100 Chinese patients in clinical studies for acute lymphoblastic leukemia — representing the largest accumulated dataset to date on CD19 CAR-T clinical safety and efficacy in a Chinese patient population."